The short version
Polycystic ovary syndrome has been officially renamed Polyendocrine Metabolic Ovarian Syndrome: PMOS. The name change was published in The Lancet on 12 May 2026, following a fourteen-year global collaboration involving 56 patient and professional organisations and more than 14,000 survey respondents. The new name better reflects what the condition actually is: a systemic hormonal and metabolic disorder, not a disease of ovarian cysts. For women who have been living with this condition and finding that clinical conversations focused narrowly on reproductive symptoms while ignoring the weight, metabolic, and mental health burden, the name change is significant. This article is about what it means and why it matters.
A Name That Was Always Incomplete
The term polycystic ovarian syndrome was coined in 1935, at a time when the condition was understood primarily as a structural problem with the ovaries. What appeared on early imaging was interpreted as cysts, and the name stuck. For nearly ninety years, it shaped the way the condition was taught, communicated, and treated.
The problem is that the name was never accurate, and the clinical consequences of that inaccuracy have been real. Women arriving at their first appointment have routinely spent time in that consultation managing fear about ovarian cysts, about surgery, about cancer, before the conversation could move on to what was actually happening. And what was actually happening has always been considerably more than a cyst story.
A companion paper published alongside the renaming confirmed what many clinicians have suspected: people with PMOS do not have a higher rate of abnormal ovarian cysts than those without the condition (Teede et al., 2026). The name was not only incomplete. It was actively misleading, and the misleading was causing clinical harm through delayed diagnosis, fragmented care, and a framing that directed attention away from the metabolic features that drive most of the condition’s burden.
What Each Word In The New Name Is Doing
Polyendocrine Metabolic Ovarian Syndrome. The name was chosen deliberately, and each word carries clinical meaning worth understanding.
Polyendocrine
The condition involves multiple interacting hormonal systems. Insulin. Androgens, particularly testosterone. The hypothalamic-pituitary-gonadal axis that governs reproductive function. Sex hormone-binding globulin. LH and FSH. The hormonal picture is genuinely complex and multi-systemic, and the prefix “poly” combined with “endocrine” signals that complexity rather than reducing it to a single organ. This is an endocrine condition first.
Metabolic
This is the word I find most clinically significant. Insulin resistance is present in an estimated 50 to 80 per cent of women with PMOS and is the central driver of many of the condition’s most consequential features: the abdominal weight gain, the elevated androgens produced by insulin-stimulated ovarian activity, the appetite dysregulation through leptin and ghrelin dysfunction, and the long-term risk of type 2 diabetes and cardiovascular disease. The metabolic dimension of this condition has been clinically central for as long as we have properly understood it. It has not been in the name before. It is in the name now, and that matters for how clinicians approach assessment and treatment.
Ovarian
“Ovarian” remains in the name, which is clinically appropriate. The ovarian consequences of the condition are real: irregular or absent ovulation, subfertility, and the endometrial health implications of infrequent cycles. Retaining “ovarian” keeps those features in clinical view without making them the defining feature of the condition.
Syndrome
“Syndrome” stays, which is honest. This is a collection of features that occur together and define the condition across a spectrum. No two women with PMOS present identically, and the syndrome framing holds that complexity. It resists the implication that there is a single test or a single treatment that fits everyone.
Why This Matters For Weight Management
The weight management dimension of this condition has been systematically underserved in clinical practice, and the name is part of the reason why.
When a condition is named after its structural appearance on imaging, treatment conversations tend to stay structural and reproductive. Women with what we called PCOS have historically been offered hormonal contraceptives to regulate cycles, and sometimes metformin if insulin resistance was recognised, and relatively little else. The insulin-driven fat accumulation, the appetite dysregulation, the abdominal fat that accumulates through mechanisms biologically distinct from general weight gain, has too often been addressed as an afterthought, or not at all.
The consequences of that are visible in clinical practice. Women in their late thirties and forties who have been living with a metabolic condition for a decade or more without that con
